Proceedings from a satellite symposium during the 42nd annual
San Antonio Breast Cancer Symposium. Featuring perspectives from
Drs Adam M Brufsky, Lisa A Carey, Sara Hurvitz and Martine J
Piccart-Gebhart.
Introduction
Program Overview: Dr Love (00:00)
Considerations in the Care of Patients with Localized
HER2-Positive Breast Cancer (BC) Receiving Neoadjuvant Systemic
Therapy
Case (Dr Brufsky): A woman in her mid-30s with
an ER-positive, HER2-positive, node-negative IDC receives
neoadjuvant TCHP and at surgery is found to have residual disease
in the breast (10:40)
Case (Dr Carey): A woman in her mid-80s with a
large ER-positive, HER2-positive, node-positive IDC has difficulty
tolerating neoadjuvant therapy and has a small amount of residual
disease in the breast at surgery (13:10)
Faculty Presentation: Dr Carey (16:53)
Adjuvant and Extended-Adjuvant Therapy for Patients
with Localized HER2-Positive BC
Case (Dr Brufsky): A woman in her early 60s
with a 1.5-cm, ER-positive, HER2-positive IDC and 3 positive
sentinel nodes (30:51)
Case (Dr Carey): A woman in her mid-40s with
ER-negative, HER2-positive, node-negative BC receives adjuvant
T-DM1 on the ATTEMPT trial (36:54)
Faculty Presentation: Dr Piccart-Gebhart (42:11)
Available Therapeutic Options for the Management of
HER2-Positive Metastatic BC (mBC)
Case (Dr Hurvitz): A woman in her early 60s
with HER2-positive mBC to the liver achieves a complete response to
THP → HP but develops CNS metastases 3 years later (52:43)
Case (Dr Piccart-Gebhart): A woman in her late
30s with heavily pretreated ER-positive, HER2-positive mBC receives
neratinib/letrozole (55:07)
Faculty Presentation: Dr Brufsky (57:51)
Novel Agents and Strategies Under Evaluation for
Patients with HER2-Positive mBC
Case (Dr Hurvitz): A woman in her late 40s
with ER-positive, HER2-positive mBC receives trastuzumab deruxtecan
on a clinical trial after disease progression on multiple lines of
therapy (1:09:56)
Case (Dr Piccart-Gebhart): A woman in her late
20s receives multiple lines of local and systemic therapy for
ER-positive, HER2-positive mBC (1:11:29)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.